DiaMedica Q2 FY26 net loss widens to $10.14 million; R&D expenses climb to $8.15 million
DMAC•Quarterly financial results
DiaMedica posted a Q2 net loss of USD 10.1 million, widening from USD 7.7 million a year earlier; loss per share was USD 0.19.
R&D expense rose to USD 8.2 million from USD 5.8 million; G&A edged up to USD 2.3 million from USD 2.2 million.
Cash position and trial updates
Cash, cash equivalents and investments fell to USD 43.5 million at June 30 from USD 59.9 million at year-end; runway forecast through 2027.
The Phase 2 early-onset fetal growth restriction trial completed enrollment for its first cohort of 6 participants; topline results are expected in September.
ReMEDy2 acute ischemic stroke trial enrollment topped 85% of the 200 participants needed for interim analysis, targeted for early 2027.
